Duloxetine API Market Research Report - Global Forecast till 2027

Duloxetine API Market Information: by Application (Major Depressive Disorder, Generalized Anxiety Disorder (GAD), Fibromyalgia, Neuropathic Pain, Chronic Musculoskeletal Pain), by Region (Americas, Europe, Asia-Pacific, Others) - Forecast till 2027

ID: MRFR/HC/6238-CR | April 2019 | Region: Global | 99 pages

Duloxetine API market is expected to register a CAGR of 3.52% and is anticipated to reach USD 3,985.0 million by 2023. Active pharmaceutical ingredients (APIs) are used in the manufacturing of pharmaceutical formulations. Duloxetine is a serotonin-norepinephrine reuptake inhibitor used in the treatment of depression and anxiety. Moreover, it is used to help relieve neuropathic pain in people with diabetes or ongoing pain due to medical conditions such as arthritis, chronic back pain, or fibromyalgia.


The growing prevalence of depression, increasing penetration of generic drugs, increasing cases of anxiety, the growing trend of outsourcing, strong drug pipeline, and growing demand for newly developed small molecule drugs are anticipated to boost the market growth over the assessment period.


Market Dynamics


The people suffering from anxiety are increasing significantly. According to a report by the World Health Organization (WHO), the portion of the global population with anxiety disorders was estimated to be 3.6% in 2015. This factor is expected to contribute to market growth. Other factors boosting the growth of the duloxetine API market include growing prevalence of depression, increasing penetration of generic drugs, increasing trend of outsourcing, strong drug pipeline among others. However, the factors such as changing economic conditions in different regions and side-effects of duloxetine may hinder the market growth over the forecast period.

Duloxetine API Market Revenue, by Application, 2017 (USD Mn) Global Duloxetine API Market Revenue, by Application, 2017 (USD Mn)


Source: MRFR Analysis


Segmentation


The duloxetine API market has been segmented into application. Based on application, the market has been segmented into major depressive disorder, generalized anxiety disorder, fibromyalgia, neuropathic pain, chronic musculoskeletal pain, and others. The chronic musculoskeletal pain accounted for a market value of USD 200.0 million in 2017.


Duloxetine API Market Share, by Region, 2017 (%) Global Duloxetine API Market Share, by Region, 2017


Source: MRFR Analysis


Regional Analysis


The duloxetine API market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.


The Americas is expected to dominate the duloxetine API market. In this region, North America is expected to dominate the market owing to the growing incidence of preventable chronic diseases such as depression, diabetes, growing government focus on generic drugs, and technological advancements in the manufacturing processes of APIs. In Europe, the market growth is due to the growing pharmaceutical sector. Moreover, countries such as the UK, Germany, and France have a higher demand for API and thus boost the growth of the overall market. The Asia-Pacific market for duloxetine API is considered to be growing significantly over the forecast period. The rising healthcare spending has led to quality healthcare becoming accessible along with a high demand for pharmaceutical products across the Asia-Pacific region. In this region, Japan accounted for a market share of 13.7% in 2017. Furthermore, the Middle East and Africa accounted for the least share of the market. The low market share is mainly due to the limited number of companies manufacturing duloxetine API.


Key Players


The prominent players in the duloxetine API market are Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Ltd (India), Aurobindo Pharma (India), Lupin (India), Zydus Cadila (India), Eli Lilly and Company (United States), Shodhana Laboratories (India), Hetero (India), Apotex Inc. (Canada), Shionogi Inc. (US), and Zhejiang Huahai Pharmaceutical Co., Ltd (China).


Some of the key strategies followed by the players operating in the fluoroscopy and mobile c-arms market were innovation, product development, acquisition, and expansion.



  • In November 2018, Sun Pharma acquired Pola Pharma, which is into R&D, manufacturing, and sales and distribution of branded and generic products in Japan.

  • In June 2017, Aurobindo acquired Generis Farmaceutica S.A. With this, the company has got access to the manufacturing and sale of pharmaceutical products in Portugal.

  • In November 2016, Sun Pharma acquired Biosintez in Russia. Biosintez is a Russian pharmaceutical company engaged in manufacturing and marketing various pharmaceutical products.

  • In March 2015, Lupin completed the acquisition of the South African generic major, Pharma Dynamics.


Market Segmentation


Duloxetine API Market, by Application



  • Major Depressive Disorder

  • Generalized Anxiety Disorder

  • Fibromyalgia

  • Neuropathic Pain

  • Chronic Musculoskeletal Pain

  • Others


Duloxetine API Market, by Region



  • Americas


    • North America


      • US

      • Canada



  • Latin America

  • Europe


    • Western Europe


      • Germany

      • UK

      • France

      • Italy

      • Spain

      • Rest of Western Europe


    • Eastern Europe




  • Asia-PacificChina


    • Japan

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific


  • Middle East & Africa


    • Middle East

    • Africa



Available Additional Customizations



  • Challenges in Duloxetine API Market


Intended Audience



  • Contract Manufacturing Organization

  • Pharmaceutical Companies

  • Government Research Organizations

  • Hospitals and Clinics

  • Regulatory Agencies



Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :


Duloxetine API market is projected to grow at a 3.52% CAGR between 2020-2027.

The Americas is expected to dominate the duloxetine API market.

Duloxetine API market is predicted to touch USD 3,985.0 million by 2023.

The chronic musculoskeletal pain segment will dominate the duloxetine API market.

Different strategies adopted by industry players in the duloxetine API market include expansion, innovation, acquisition, and product development.



This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.